
Abstral® is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral® allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.
Short facts | |
Technology | Sublingual |
Indication | Breakthrough cancer pain |
Market approvals | US, EU, RoW among others Japan, Australia, Saudi Arabia and South Korea |
Commercial rights | RoW, Kyowa Kirin |
Partner | ![]() |
Patent protection | On RoW markets until 2024. For the US and the EU the patents expired in September 2019. |
The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral® is currently available in key markets such as Japan, Australia and South-Korea. Globally, the market for Abstral® has continued to grow rapidly over the years.